Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life

Eur J Cancer. 2016 Dec:69:110-118. doi: 10.1016/j.ejca.2016.10.004. Epub 2016 Nov 4.

Abstract

Aim: Early palliative care (EPC) in oncology has shown sparse evidence of a positive impact on patient outcomes, quality of care outcomes and costs.

Patients and methods: Data for this secondary analysis were taken from a trial of 207 outpatients with metastatic pancreatic cancer randomly assigned to receive standard cancer care plus on-demand EPC (standard arm) or standard cancer care plus systematic EPC (interventional arm). After 20 months' follow-up, 149 (80%) had died. Outcome measures were frequency, type and timing of chemotherapy administration, use of resources, place of death and overall survival.

Results: Some indices of end-of-life (EoL) aggressiveness had a favourable impact from systematic EPC. Interventional arm patients showed higher use of hospice services: a significantly longer median and mean period of hospice care (P = 0.025 for both indexes) and a significantly higher median and mean number of hospice admissions (both P < 0.010). In the experimental arm, chemotherapy was performed in the last 30 days of life in a significantly inferior rate with respect to control arm: 18.7% versus 27.8% (adjusted P = 0.036). Other non-significant differences were seen in favour of experimental arm.

Conclusions: Systematic EPC showed a significant impact on some indicators of EoL treatment aggressiveness. These data, reinforced by multiple non-significant differences in most of the other items, suggest that quality of care is improved by this approach. This study is registered on ClinicalTrials.gov (NCT01996540).

Keywords: Care aggressiveness near the end of life; Early palliative care; Use of health care services.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Delivery of Health Care / methods
  • Female
  • Hospice Care / statistics & numerical data*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Palliative Care / methods*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy*
  • Quality of Health Care*
  • Quality of Life*
  • Terminal Care / standards*
  • Time Factors

Substances

  • Antineoplastic Agents

Associated data

  • ClinicalTrials.gov/NCT01996540